A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of LG00034053 in Patients With Knee OA
Status:
Recruiting
Trial end date:
2023-12-30
Target enrollment:
Participant gender:
Summary
This study is a multi-center, randomized, placebo-controlled, double-blind clinical study,
consisting of Part 1 (Phase 1b) in a sequential, dose-escalating design and Part 2 (Phase 2)
in a parallel design.